The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
The FDA has removed the risk evaluation and mitigation strategies (REMS) program requirement for Tryvio (aprocitentan).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback